论文部分内容阅读
Background:The role ofpostradiation systemic therapy in non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) was controversial.Thus,we explored the role of Radiation Therapy Oncology Group recursive partitioning analysis (RTOG-RPA) and graded prognostic assessment (GPA) in identifying population who may benefit from postradiation systemic therapy.Methods:The clinical data of NSCLC patients with documented BM from August 2007 to April 2015 of two hospitals were studied retrospectively.Cox regression was used for multivariate analysis.Survival of patients with or without postradiation systemic therapy was compared in subgroups stratified according to RTOG-RPA or GPA.Results:Of 216 included patients,67.1％ received stereotactic radiosurgery (SRS),24.1％ received whole-brain radiation therapy (WBRT),and 8.8％ received both.After radiotherapy,systemic therapy was administered in 58.3％ of patients.Multivariate analysis found that postradiation systemic therapy (yes vs.no) (hazard ratio [HR] =0.36 l,95％ confidence interval [CI] =0.202-0.648,P =0.001),radiation technique (SRS vs.WBRT) (HR =0.462,95％ CI =0.238-0.849,P =0.022),extracranial metastasis (yes vs.no) (HR =3.970,95％ CI =1.757-8.970,P =0.001),and Kamofsky performance status (＜70 vs.≥70) (HR =5.338,95％ CI =2.829-10.072,P ＜ 0.001) were independent factors for survival.Further analysis found that subsequent tyrosine kinase inhibitor (TKI) therapy could significantly reduce the risk of mortality of patients in RTOG-RPA Class IⅡ (HR =0.411,95％ CI =0.183-).923,P =0.031) or with a GPA score of 1.5-2.5 (HR =0.420,95％ CI =0.182-0.968,P =0.042).However,none of the subgroups stratified according to RTOG-RPA or GPA benefited from the additional conventional chemotherapy.Conclusion:RTOG-RPA and GPA may be useful to identify beneficial populations in NSCLC patients with BM ifTKIs were chosen as postradiation systemic therapy.